540 related articles for article (PubMed ID: 26033251)
1. Antifungal drug resistance among Candida species: mechanisms and clinical impact.
Sanguinetti M; Posteraro B; Lass-Flörl C
Mycoses; 2015 Jun; 58 Suppl 2():2-13. PubMed ID: 26033251
[TBL] [Abstract][Full Text] [Related]
2. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
[TBL] [Abstract][Full Text] [Related]
3. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing offers new insights into the resistance of Candida spp. to echinocandins and azoles.
Garnaud C; Botterel F; Sertour N; Bougnoux ME; Dannaoui E; Larrat S; Hennequin C; Guinea J; Cornet M; Maubon D
J Antimicrob Chemother; 2015 Sep; 70(9):2556-65. PubMed ID: 26017039
[TBL] [Abstract][Full Text] [Related]
5. Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon.
Dos Santos Abrantes PM; McArthur CP; Africa CW
Diagn Microbiol Infect Dis; 2014 Jun; 79(2):222-7. PubMed ID: 24726686
[TBL] [Abstract][Full Text] [Related]
6. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
[TBL] [Abstract][Full Text] [Related]
7. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Pfaller MA; Castanheira M; Messer SA; Jones RN
Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
[TBL] [Abstract][Full Text] [Related]
8. Resistance of Candida to azoles and echinocandins worldwide.
Pristov KE; Ghannoum MA
Clin Microbiol Infect; 2019 Jul; 25(7):792-798. PubMed ID: 30965100
[TBL] [Abstract][Full Text] [Related]
9. Antifungal drug resistance mechanisms.
Pemán J; Cantón E; Espinel-Ingroff A
Expert Rev Anti Infect Ther; 2009 May; 7(4):453-60. PubMed ID: 19400764
[TBL] [Abstract][Full Text] [Related]
10. Tipping the balance both ways: drug resistance and virulence in Candida glabrata.
Vale-Silva LA; Sanglard D
FEMS Yeast Res; 2015 Jun; 15(4):fov025. PubMed ID: 25979690
[TBL] [Abstract][Full Text] [Related]
11. Update on antifungal resistance in Aspergillus and Candida.
Arendrup MC
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():42-8. PubMed ID: 24372701
[TBL] [Abstract][Full Text] [Related]
12. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review.
Mishra NN; Prasad T; Sharma N; Payasi A; Prasad R; Gupta DK; Singh R
Acta Microbiol Immunol Hung; 2007 Sep; 54(3):201-35. PubMed ID: 17896473
[TBL] [Abstract][Full Text] [Related]
13. Azole susceptibility and resistance in Candida dubliniensis.
Pinjon E; Moran GP; Coleman DC; Sullivan DJ
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1210-4. PubMed ID: 16246083
[TBL] [Abstract][Full Text] [Related]
14. The yeast, the antifungal, and the wardrobe: a journey into antifungal resistance mechanisms of
Oliveira JS; Pereira VS; Castelo-Branco DSCM; Cordeiro RA; Sidrim JJC; Brilhante RSN; Rocha MFG
Can J Microbiol; 2020 Jun; 66(6):377-388. PubMed ID: 32319304
[No Abstract] [Full Text] [Related]
15. Clinical Significance of the Floral Shift in Candidiasis.
Raj AT; Patil S; Sujatha G; Seetharam C; Kader NA
J Contemp Dent Pract; 2018 Oct; 19(10):1161-1162. PubMed ID: 30498168
[No Abstract] [Full Text] [Related]
16. Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients.
Chunchanur SK; Nadgir SD; Halesh LH; Patil BS; Kausar Y; Chandrasekhar MR
Indian J Pathol Microbiol; 2009; 52(4):501-4. PubMed ID: 19805956
[TBL] [Abstract][Full Text] [Related]
17. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):278-83. PubMed ID: 20846808
[TBL] [Abstract][Full Text] [Related]
18. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
19. [In vitro resistance of Candida species to antifungal agents].
Banach-Piatkowska W; Kotłowski A; Humanowska J; Mayer L; Kowalczyk D
Wiad Parazytol; 2001; 47(4):811-6. PubMed ID: 16886432
[TBL] [Abstract][Full Text] [Related]
20. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
